Arbutus Biopharma (ABUS) Asset Utilization Ratio (2014 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Asset Utilization Ratio of 1.03 for Q1 2026, up 1900.22% year-on-year from 0.05 in Q1 2025, and up 603.24% on a QoQ basis from 0.15 in Q4 2025.
Arbutus Biopharma (ABUS) Asset Utilization Ratio (2014 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Asset Utilization Ratio for 13 consecutive years, with 1.03 the latest figure, recorded in Q1 2026.
- Quarterly Asset Utilization Ratio rose 1900.22% year-over-year to 1.03 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.03 (up 1900.22% YoY) and the FY2025 annual result came in at 0.12, up 178.41% from the prior year.
- Asset Utilization Ratio rose to 1.03 in Q1 2026 per ABUS's latest filing, from 0.15 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for ABUS reached as high as 1.03 in Q1 2026 and fell as low as 0.04 in Q3 2024.
- A 5-year average of 0.17 and a median of 0.13 in 2023 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio plunged 66.16% — and 2026, when it jumped 1900.22%.
- Year by year, Asset Utilization Ratio stood at 0.2 in 2022, then plunged by 38.75% to 0.12 in 2023, then sank by 62.12% to 0.05 in 2024, then soared by 222.93% to 0.15 in 2025, then soared by 603.24% to 1.03 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 1.03, 0.15, and 0.15 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 1.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 |
| Dec 31, 2025 | 0.15 |
| Sep 30, 2025 | 0.15 |
| Jun 30, 2025 | 0.14 |
| Mar 31, 2025 | 0.05 |
| Dec 31, 2024 | 0.05 |
| Sep 30, 2024 | 0.04 |
| Jun 30, 2024 | 0.06 |
| Mar 31, 2024 | 0.09 |
| Dec 31, 2023 | 0.12 |
| Sep 30, 2023 | 0.13 |
| Jun 30, 2023 | 0.13 |
| Mar 31, 2023 | 0.17 |
| Dec 31, 2022 | 0.20 |
| Sep 30, 2022 | 0.17 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | 0.10 |
| Dec 31, 2021 | 0.06 |
| Sep 30, 2021 | 0.07 |
| Jun 30, 2021 | 0.06 |